AnGes Inc
5
67M
4
0.21
2
0.20
- Areas of investment
Summary
AnGes Inc appeared to be the Corporate Investor, which was created in 1999. The company was established in Asia in Japan. The main office of represented Corporate Investor is situated in the Tokyo.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - Germany. Among the various public portfolio startups of the fund, we may underline Dolthera GmbH Among the most successful fund investment fields, there are Health Care, Pharmaceutical. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2005.
The standard case for the fund is to invest in rounds with 3 partakers. The meaningful sponsors for the fund in investment in the same round are Takeda Ventures, Innovations Kapital, Deutsche Venture Capital. In the next rounds fund is usually obtained by German Federal Ministry of Education and Research (BMBF).
Investments analytics
Analytics
- Total investments
- 5
- Lead investments
- 2
- Rounds per year
- 0.21
- Follow on index
- 0.20
- Investments by industry
- Pharmaceutical (4)
- Biotechnology (4)
- Health Care (2)
- Therapeutics (2)
- mHealth (1) Show 2 more
- Investments by region
-
- United States (2)
- Germany (1)
- Israel (1)
- Japan (1)
- Peak activity year
- 2020
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Avg. valuation at time of investment
- 4M
- Group Appearance index
- 0.60
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| MyBiotics Pharma | 15 Aug 2018 | Biotechnology, Health Care, Wellness, Pharmaceutical | Early Stage Venture | 8M | HaMerkaz, Rehovot, Israel |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.